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OBJECTIVES To assess the effects of aspirin compared with simvastatin on thrombin generation in
hypercholesterolemic men, and to establish whether the reduction of elevated blood
cholesterol by simvastatin would affect the action of aspirin on thrombin formation.
BACKGROUND Aspirin inhibits thrombin formation, but its performance is blunted in hypercholesterolemia.
By virtue of altering lipid profile, statins could be expected to influence thrombin generation.
METHODS Thirty-three men, aged 34 to 61 years, with minimal or no clinical symptoms, serum total
cholesterol .6.5 mmol/liter and serum triglycerides ,4.6 mmol/liter, completed the study
consisting of three treatment phases. First, they received 300 mg of aspirin daily for two weeks
(phase I), which was then replaced by simvastatin at the average dose of 24 mg/d for three
months (phase II). In phase III, aspirin, 300 mg/day, was added for two weeks to simvastatin,
the dose of which remained unchanged. Thrombin generation was assessed: 1) in vivo, by
measuring levels of fibrinopeptide A (FPA) and prothrombin fragment 112 (F112) in
venous blood; and 2) ex vivo, by monitoring the rates of increase of FPA and F112 in blood
emerging from standardized skin incisions of a forearm. A mathematical model was used to
describe the kinetics of thrombin formation at the site of microvascular injury.
RESULTS Two-week treatment with aspirin had no effect on thrombin markers in vivo, while ex vivo
it depressed the total amount of thrombin formed, though not the reaction rate. After
simvastatin treatment, serum cholesterol decreased by 31% and LDL cholesterol by 42%,
while thrombin generation became markedly depressed. In venous blood, FPA was signifi-
cantly reduced. Concomitantly, the initial thrombin concentration and total amount of
thrombin generated decreased significantly. Addition of aspirin to simvastatin (phase III) had
no further effect on any of these parameters.
CONCLUSIONS In men with hypercholesterolemia, lowering serum cholesterol level by a three-month
simvastatin treatment is accompanied by a marked reduction of thrombin generation both at
basal conditions in venous blood and after activation of hemostasis by microvascular injury.
Once blood cholesterol became reduced, adding aspirin to simvastatin did not enhance
dampening of thrombin formation. (J Am Coll Cardiol 1999;33:1286–93) © 1999 by the
American College of Cardiology
The link between hypercholesterolemia and atherosclerosis
is well established, and recent studies (1–3) demonstrated
that lowering serum cholesterol, particularly with statins,
See page 1305
(3-hydroxy-3-methylglutaryl-CoA reductase inhibitors),
decreases cardiovascular events in patients with and without
coronary artery disease. Hypercholesterolemia may predis-
pose to coronary heart disease by several mechanisms,
including hypercoagulability. Indeed, in hypercholester-
olemic subjects, platelet aggregability is enhanced, throm-
boxane A2 production is increased, and markers of throm-
bin generation are elevated in venous blood (4–6). Aspirin
effectively blocks platelet aggregation (7) and inhibits
thrombin generation in the clotting blood (8), which ex-
plains its beneficial prophylactic and therapeutic effects in
atherothrombotic disease. However, in hypercholesterol-
emia, the inhibitory effect of aspirin on thrombin generation
is blunted (9).
Statins, by altering blood lipids profile, could modulate
thrombin production and its activity. Therefore, in hyper-
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cholesterolemic men, we compared the effects of simvastatin
versus aspirin on thrombin generation. We also investigated
whether reduction in elevated serum cholesterol would
restore the inhibitory effect of aspirin on thrombin forma-
tion to its full potential. For this purpose, we evaluated the
effects of a two-week treatment with aspirin on thrombin
generation before and after lowering serum cholesterol levels
with simvastatin.
METHODS
Patients. Patients were recruited through the outpatient
lipid clinic, to which they had been referred for evaluation of
elevated blood lipids or because of the history of hyperlip-
idemia in the family.
Male patients with serum total cholesterol .6.5 mmol/
liter (250 mg/dL) and triglycerides ,4.6 mmol/liter
(400 mg/dL), not responding to dietary treatment alone,
were eligible to enter the study. Exclusion criteria included:
aged .65 or ,30 years, unstable coronary heart disease,
diabetes mellitus and other severe chronic illness (eg, can-
cer), active peptic ulcer, impaired hepatic or renal function,
secondary hypercholesterolemia, history of alcoholism, sys-
tolic blood pressure greater than 180 mm Hg and/or a
diastolic blood pressure greater than 100 mm Hg and use of
other hypolipemic drugs. Participants did not take any
medication that could possibly interfere with hemostatic
parameters for one month before the start of the study.
They were on a standard lipid-lowering diet [phase 1
according to the American Heart Association (10)] for at
least 6 weeks before entering the trial and throughout it.
All subjects gave informed consent, and the protocol was
approved by the University Ethical Committee.
Drug regimens. Study protocol comprised three treatment
phases. First, the patients received 300 mg of aspirin daily
for two weeks (week 0–2; phase I). Thereafter, they entered
a 12-week active treatment with simvastatin (week 3–14;
phase II), which was begun with the dose of 20 mg once a
day with the evening meal. If total cholesterol level did not
fall by at least 1 mmol/liter after four weeks of the drug
administration, the dose was increased to 40 mg. After a
three-month simvastatin treatment, aspirin (300 mg/d) was
added for two weeks to simvastatin, the dose of which
remained unchanged (ie, 20 or 40 mg/d; week 15–16; phase
III).
Laboratory investigations. Blood was sampled in the
morning after 16 h of fasting. Smokers were requested not
to smoke for at least 2 h before blood sampling. At entry
(week 0), after six weeks (week six) and at the end of the
study (week 16), the following estimations were performed:
blood morphology and platelet count, serum creatinine,
bilirubin, aspartate (AST) and alanine aminotransferases
(ALT), alkaline phosphatase (AP), creatine phosphokinase
(CK) and urinalysis.
Total cholesterol (TC), high-density lipoprotein choles-
terol (HDL-C) and triglycerides (TG) were determined by
standard procedures in serum. Serum low-density lipopro-
tein cholesterol (LDL-C) levels were calculated by the
Friedewald formula. Lipid profile was determined five
times: before starting therapy (week 0), after the first (week
6), the second (week 10), and the third month (week 14) of
treatment with simvastatin and at the end of the study
(week 16). The primary criterion used to evaluate the
efficacy of treatment was TC. A posttreatment reduction by
more than 1 mmol/L was chosen as the therapeutic goal. If
such reduction was not obtained, the patient was excluded
from the final analysis.
Safety assessments included vital signs, a 12-lead electro-
cardiogram (ECG) and laboratory tests (AST, ALT, and
CK), performed monthly during simvastatin treatment.
Notable increase was defined as more than threefold rise
above the upper limit of normal range of ALT or AST, or
more than 10-fold rise above the upper limit of normal
range of CK on any occasion. The notable rise in one of
these three enzymes levels was the reason for discontinua-
tion of simvastatin administration.
Hemostatic variables measured included: fibrinogen,
plasminogen, antithrombin III, prothrombin, platelet ag-
gregation induced by arachidonic acid (AA) and thrombin
generation in vivo and ex vivo. They were assessed at
baseline (week 0), after two weeks of aspirin administration
(phase I), after three months of simvastatin treatment
(phase II) and after final two weeks of combined aspirin and
simvastatin (phase III) therapy. Blood was collected into
3.8% sodium citrate (9:1, vol/vol).
Platelet aggregation by arachidonic acid (AA) was mea-
sured in platelet-rich plasma. If platelets did not respond to
1.2 mmol AA, the subjects were considered to be under the
probable influence of platelet-inhibiting drugs and they did
not enter the study. Platelet aggregability was also tested at
week 14, after three months of simvastatin therapy.
Plasma fibrinogen, plasminogen, antithrombin III and
prothrombin concentrations were determined nephelomet-
rically (Dade Behring, Marburg, Germany).
Thrombin generation in vivo was measured in peripheral
venous blood using two specific markers: fibrinopeptide A
(FPA) (Asserachrom; Diagnostica Stago, Asnie`res, France)
Abbreviations and Acronyms
ALT 5 alanine aminotransferase
AP 5 alkaline phosphatase
AST 5 aspartate aminotransferase
CK 5 creatine phosphokinase
F112 5 prothrombin fragments 112
FPA 5 fibrinopeptide A
HDL 5 high-density lipoprotein
LDL 5 low-density lipoprotein
TAT 5 thrombin-antithrombin III complexes
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and prothrombin fragment 112 (F112) (Enzygnost;
Behring, Germany).
The thrombin generation ex vivo assay consisted of
monitoring the rates of increase of FPA and F112 concen-
trations in blood emerging from standardized skin incisions
of a forearm. The details of the method were described
previously (9,11). Briefly, skin incisions were made on a
forearm with a Simplate II device (Organon Teknika).
Blood aliquots were collected into heparinized canules
(Baxter) at 30-s intervals and immediately mixed with
anticoagulant (Byk Gulden, Konstarz, Germany) in plastic
tubes (1:10, vol/vol). They were centrifuged at 3,000 rpm
for 20 min at 4°C and stored for two months at 280°C until
assayed. Volumes of consecutive blood samples were also
recorded. To minimize technical limitations of the method
pertaining to sample collection and analysis, all the proce-
dures were performed by the same investigators. The
concentrations of FPA were expressed in ng/mL, and those
of F112 in nmol/liter.
Data were analyzed by comparing FPA or F112 levels at
the same time intervals, before and after the specific drug
treatment. In addition, the kinetics of thrombin generation
at sites of microvascular injury was calculated using a
mathematical model, reported in detail elsewhere (9). Ac-
cording to the model, plasma concentrations of FPA or
F112 at any time point can be determined using the
equation:
c~t! 5 coexp ~lt!,
where co denotes the calculated concentration of the throm-
bin marker at the very beginning of bleeding, and l
represents the rate of its increase. Parameter S, calculated as
the area under the curve, is a measure of the total amount of
thrombin generated in 3 min (Fig. 1).
Statistical analysis. Two-way repeated measure analysis of
variance (ANOVA) was used wherever its assumptions were
fulfilled. The majority of variables did not meet ANOVA
criteria, and Friedman’s test was applied followed by paired
analysis using Wilcoxon matched pairs test. Statistical
significance was accepted at a level of p , 0.05. Calculations
were performed on a PC computer with Statistica (StatSoft,
Inc., Tulsa, Oklahoma).
RESULTS
Subjects and treatment. Thirty-eight men entered the
study. Three presented with intermittent claudication
(grade II according to Fontaine), five had mild arterial
hypertension and one had coronary heart disease. No other
clinical pathology was evident. None of the subjects had
history of venous thromboembolism. Two received enala-
pril, one metoprolol and one molsidomine and isosorbide
mononitrate. Twenty were current smokers.
Two subjects were withdrawn from the study: one be-
cause of nonfatal acute myocardial infarction that occurred
6 weeks after the onset of the study and another because of
subarachnoid hemorrhage with short-lived neurological
symptoms, which occurred 8 weeks after the start of the
study. These two serious adverse events could not be
definitely attributed to simvastatin therapy.
Nine patients received 40 mg simvastatin daily; the
remaining received 20 mg a day. Overall, tolerability of
simvastatin was good. Most laboratory safety values re-
mained within the normal range. No notable increases in
AST, ALT or CK levels were recorded during the study.
There was no significant change in blood pressure, heart
rate, clinical symptoms or ECG recordings during the
study.
Three patients were excluded from the final analysis,
because of insufficient reduction in cholesterol level (on
average, 0.5 mmol/liter). Thus, the final analysis comprised
data from 33 subjects, aged 34 to 61 (mean, 47.4) years.
Blood lipids and hemostatic parameters. Simvastatin
treatment resulted in a significant decrease in total choles-
terol, LDL cholesterol, and triglycerides (Table 1). Plasma
fibrinogen, prothrombin, antithrombin III and plasminogen
Figure 1. Thrombin generation as a function of time, c(t). co
denotes the initial thrombin generation, l determines the rate of
increase of the curve and S denotes the total amount of thrombin
generated in the first 180 s, reflected by the shaded area under the
curve.
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levels did not change during the study. Bleeding time
became markedly prolonged only when aspirin was used.
Thrombin generation in vivo. Administration of aspirin
for 2 weeks at a dose of 300 mg daily did not affect the levels
of either FPA or F112. On the contrary, 12-week simva-
statin treatment significantly reduced FPA concentration.
Addition of aspirin to simvastatin for 2 weeks had no
further effect (Table 1).
Thrombin generation ex vivo. In blood emerging from
the standardized skin incisions, FPA and F112 levels
increased exponentially and reached a plateau at approxi-
mately 4 min, when blood flow decreased. Six measure-
ments of both FPA and F112 were performed in each
subject before and after the drug.
1/FPA FORMATION. After two weeks of treatment with
aspirin, FPA values became significantly decreased at 90,
150 and 180 s, but not at other time points of blood
sampling. Simvastatin treatment significantly reduced FPA
values at 90, 120 and 180 s. Addition of aspirin to
simvastatin treatment for two weeks did not produce any
further depression of FPA concentrations (Table 2). Vol-
umes of blood samples did not affect FPA concentrations.
Analysis of the kinetics of thrombin formation, using the
mathematical model, revealed that both aspirin and simva-
statin used separately depressed the total amount of throm-
bin generated (S). Addition of aspirin to simvastatin (phase
III) had no further effect on this parameter (Table 3).
2/F112 FORMATION. Both drug regimens, administered
separately, depressed significantly F112 formation at all
time intervals studied as compared with the baseline values
(Table 2, Fig. 2). There was no relationship between
volumes of blood samples and F112 concentrations. After
simvastatin, the average values were usually lower than after
aspirin therapy, but the difference between the two regimens
reached the significance only at time 30 s. Depression of
thrombin generation remained at the same level when both
drugs were administered in combination for the last two
weeks. Of parameters describing the thrombin generation
curve, both initial thrombin concentration (co), and total
amount of thrombin generated (S) became depressed after
treatment with either aspirin or simvastatin (Table 3).
DISCUSSION
Design of the study and methods used. We designed the
study to compare the effects of aspirin on thrombin gener-
ation with those of simvastatin, and to evaluate the possi-
bility that reduction of elevated blood cholesterol levels may
improve aspirin-induced changes in thrombin formation.
We, therefore, studied the generation of thrombin at
baseline and after a two-week treatment with aspirin fol-
lowed by administration of a potent cholesterol-lowering
agent, simvastatin. At the end of this period, we assessed
thrombin generation, added aspirin to simvastatin for twoTa
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weeks and then repeated thrombin generation measure-
ments.
To assess thrombin formation in vivo, we determined
concentrations of two specific and sensitive markers in
venous blood. Although they both reflect the appearance of
thrombin, their origin is not the same (12). F112 is a
polypeptide cleaved from prothrombin during its conversion
to thrombin, and FPA is split off from fibrinogen by
thrombin. Thus, F112 reflects the final stage in the process
of thrombin formation, while FPA is a measure of thrombin
activity. The same two markers were used in the ex vivo
method, based on the sampling of blood coming out from
standardized skin incisions. The technique has been intro-
duced into coagulation studies by Thorngren et al. (13), and
successfully applied by other investigators (14–16). A math-
ematical model describing the process of thrombin forma-
tion ex vivo has been developed (11).
Aspirin and thrombin formation. There is convincing
evidence that aspirin inhibits effectively thrombin formation
(11,14). After a two-week administration at a dose of
300 mg per day, it significantly reduced thrombin markers
in venous blood and depressed thrombin formation in
skin-bleeding-time blood (9). These effects were observed
in subjects with average cholesterol levels, but were blunted
in patients with marked hypercholesterolemia (9). The
present study confirms the previous observations on reduced
capacity of aspirin to inhibit thrombin formation in hyper-
cholesterolemic men, particularly when assessed by changes
in FPA concentrations. Thus, in vivo both thrombin mark-
ers remained unaffected by aspirin treatment, while the
velocity of the reaction did not change at sites of the
microvasculature injury. Furthermore, ex vivo aspirin did
not depress significantly FPA concentrations at some blood
sampling points, though the total amount of thrombin
generated within 3 min was significantly reduced. Assess-
ment of F112 curve showed more consistent inhibition by
aspirin.
Simvastatin treatment. A 12-week simvastatin therapy led
to a marked reduction in blood total and LDL cholesterol.
This was accompanied by depression of thrombin generation,
as evidenced by decreased concentrations of FPA in venous
blood, unaffected by the preceding aspirin treatment. In skin-
Table 2. Prothrombin Fragment 112 (F112) and Fibrinopeptide A (FPA) in Blood Ex Vivo
Time (s) Baseline Phase I Phase II Phase III p
F112 (nmol/liter)
30 15.91 (4.54; 31.09) 5.19 (3.47; 9.48)* 2.70 (1.70; 5.05)*‡ 2.25 (1.32; 3.90)*‡ , 0.00001
60 19.35 (6.80; 51.60) 7.40 (4.22; 16.17)* 4.80 (2.00; 10.10)* 4.80 (2.49; 11.00)* 0.002
90 34.41 (16.35; 80.50) 11.70 (3.10; 28.32)* 7.60 (3.72; 21.60)† 8.65 (4.94; 15.45)* 0.0007
120 49.35 (18.50; 80.66) 16.40 (7.90; 66.08)* 17.20 (5.18; 38.40)* 11.31 (5.68; 32.72)*‡ 0.002
150 72.90 (43.10; 17.70) 25.20 (10.60; 72.68)† 21.20 (10.80; 50.80)* 22.40 (11.66; 49.57)* 0.0003
180 97.30 (41.00; 224.48) 39.17 (16.90; 106.67)† 32.80 (13.60; 74.55)* 38.60 (16.20; 58.47)* 0.0003
FPA (ng/mL)
30 344.7 (193.6; 911.1) 267.7 (98.5; 404.6) 192.7 (119.1; 382.3) 243.4 (139.9; 361.2) NS
60 623.8 (322.5; 976.8) 498.9 (292.1; 776.9) 427.5 (235.3; 734.2) 416.7 (240.9; 799.7) NS
90 1053.1 (535.6; 1634.5) 585.0 (278.0; 934.5)* 547.1 (292.8; 991.6)* 569.8 (323.6; 926.6)* 0.0008
120 1070.7 (660.8; 1716.6) 845.0 (460.1; 1334.3) 817.4 (339.3; 1008.2)*‡ 597.1 (366.6; 1048.1)*‡ 0.0001
150 1593.8 (1161.9; 2773.9) 962.8 (632.1; 1629.3)* 1213.5 (887.7; 1878.2)† 1215.8 (859.4; 2338.1) 0.04
180 1854.8 (1264.5; 2750.4) 1031.8 (882.3; 1997.4) 2442.2 (1057.4; 2932.2) 1625.1 (1136.1; 2816.4) NS
Values are median (quartile 1;3). Friedman’s test was applied followed by paired analysis using Wilcoxon test:
*p # 0.005 as compared with baseline, †p # 0.05 as compared with baseline, ‡p , 0.05 as compared with phase I.
Table 3. Kinetics of Thrombin Generation Based on Concentrations of Prothrombin Fragment 112 (F112) and Fibrinopeptide A
(FPA) in Blood Ex Vivo
Parameter Baseline Phase I Phase II Phase III p
F112
l 0.011 (0.008; 0.017) 0.013 (0.010; 0.017) 0.015 (0.011; 0.020)† 0.016 (0.013; 0.018)† 0.004
co 11.56 (6.43; 23.25) 4.55 (2.55; 8.16)* 2.42 (1.12; 4.72)† 2.06 (1.08; 4.95)* 0.00008
S 43.44 (21.44; 85.01) 18.36 (9.30; 53.41)* 13.70 (7.67; 34.99)† 15.34 (7.99; 25.60)* 0.006
FPA
l 0.009 (0.004; 0.013) 0.011 (0.006; 0.014) 0.011 (0.009; 0.015) 0.011 (0.008; 0.013) NS
co 387.8 (216.6; 783.7) 239.7 (97.0; 479.5) 234.3 (114.1; 398.8) 223.1 (145.3; 407.6) NS
S 989.7 (727.6; 1561.9) 714.4 (445.0; 1057.5)† 783.0 (562.3; 1122.6)† 790.8 (475.9; 1181.2)† 0.01
Values are median (quartile 1;3). Friedman’s test was applied followed by paired analysis using Wilcoxon test:
*p # 0.0005 as compared to baseline, †p # 0.01 as compared with baseline, ‡p , 0.05 as compared with phase I.
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bleeding-time blood, the amount of thrombin formed also
became significantly reduced. This effect was reflected by
changes in two parameters describing the kinetics of thrombin
formation: the initial thrombin concentration and total amount
of thrombin generated in 3 min, which decreased significantly.
This considerable decrease in thrombin generation by simva-
statin was not enhanced by an additional supplementation of
aspirin for two weeks.
While this work was in progress, three reports appeared
suggesting that cholesterol reduction by statins might de-
crease the thrombogenic potential in hypercholesterolemia.
Aoki and colleagues (17) observed that pravastatin, admin-
istered at a dose of 15 mg/day to patients with hypercho-
lesterolemia for at least one month, reduced platelet-
dependent thrombin formation, measured in vitro in
recalcified plasma, though thrombin-antithrombin III
(TAT) complexes in venous blood remained unchanged.
Lacoste and colleagues (18) reported that pravastatin at a
dose of 40 mg/day administered for 2.5 months to 16
hypercholesterolemic patients reduced platelet thrombus
formation, assessed by the exposure of porcine aortic media
to the patients’ flowing venous blood in an ex vivo super-
fusion chamber. DiGarbo et al. (19) concluded that simva-
statin inhibits initially augmented thrombin formation in
hypercholesterolemia, as reflected by a significant posttreat-
ment fall in plasma TAT and F112 concentrations. Both
Aoki’s and Lacoste’s groups expressed the view that the
effects they observed were not due to a direct action of
pravastatin on hemostasis but to cholesterol lowering. Thus,
pravastatin added to recalcified plasma did not affect the
production of thrombin in test tubes (17), and thrombus
formation was unchanged after 1 week of pravastatin treat-
ment, when serum cholesterol levels were not reduced yet
(18). Our results corroborate and extend the recent findings
by DiGarbo et al. (19), indicating that statins not only
decrease steady-state thrombin generation in peripheral
venous blood, but also lower its formation when hemostatic
system is activated by a microvascular injury.
Statins exert their beneficial effects on coronary events rate
also in patients with average blood cholesterol levels (3,20).
Thus, it remains to be established whether highly desirable
clinical benefits from successful statin therapy depend solely on
the lipid-lowering effect or on a different mechanism, e.g., an
influence on the expression of tissue factor or endothelial
function (vide infra). A reduction of thrombogenic potential
might not be specific for statins. Gemfibrozil, a lipid-lowering
drug with a different mechanism of action, has been reported to
lower F112 and TAT levels in venous blood, which was
associated with normalization of plasma lipids in men with
combined hyperlipidemia (21).
Recently, it has been found that simvastatin reduces the
expression of tissue factor in cultured human macrophages
(22) and in monocytes of subjects with hypercholesterol-
emia (23). This effect could well explain a distinct depres-
sion of thrombin generation in the ex vivo model used in the
present study, because increased expression of tissue factor
Figure 2. Thrombin generation expressed as concentrations of
prothrombin fragment 112 (F112) as a function of time, at
baseline and after phase I, II and III.
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starts an exponential thrombin generation at sites of micro-
vascular injury (16). Improvement in endothelial function,
found after four weeks of simvastatin treatment (24), cou-
pled with decreased adhesion of monocytes to endothelial
cells (25), would also favor stricter control or even decreased
thrombin formation. Simvastatin, by normalizing platelet
lipid composition and membrane fluidity in hypercholester-
olemic patients (26), may also attenuate platelet involve-
ment in thrombin generation (27). The influence of simva-
statin on platelet function in hypercholesterolemia has been,
however, questioned (28).
Clinical relevance. Our results indicate that in hypercho-
lesterolemia, lowering of total and LDL cholesterol with
simvastatin is accompanied by a marked reduction in
thrombin generation; the kinetics of thrombin formation in
blood becomes considerably depressed. This effect of sim-
vastatin on thrombin production is more pronounced than
that of aspirin. Importantly, once serum cholesterol concen-
tration became reduced, adding aspirin to simvastatin does
not lead to any further suppression of thrombin formation.
When designing the study we anticipated that simvasta-
tin, by altering lipid profile, would set the stage for aspirin
to express its full capacity to inhibit thrombin generation.
We did not expect that lipid-lowering treatment with
simvastatin will be associated with such a profound reduc-
tion in thrombin formation. Aspirin was unable to suppress
further thrombin generation, so effectively controlled by
simvastatin; no additive or synergistic effects were observed.
Perhaps, counterregulatory mechanisms oppose an addi-
tional dampening of thrombin generation, or simvastatin
through poorly defined alterations in membrane lipid profile
renders proteins less accessible for the acetylation induced
by aspirin. It should not be concluded that there is no room
for aspirin in hypercholesterolemic subjects whose choles-
terol became successfully reduced by simvastatin, since
aspirin has been proven to produce some of its beneficial
effects through several mechanisms unrelated to thrombin
generation (7).
In summary, our study shows that in hypercholesterol-
emia, lowering blood cholesterol by simvastatin treatment is
associated with a reduction in thrombin generation both at
basal conditions in venous blood and after activation of
hemostasis by microvascular injury. The marked inhibitory
effect of simvastatin on thrombin formation, observed as
early as three months after the onset of therapy, might be of
special clinical interest. It could also suggest that early
clinical benefits observed during treatment with statins
(3,20) might be due, at least in part, to a decrease in
thrombogenic potential and might precede atherosclerotic
plaque stabilization or regression.
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